Climb Bio Inc’s recent filing unveils that its Director RA CAPITAL MANAGEMENT, L.P. acquired Company’s shares for reported $24888.0 on Jan 05 ’26. In the deal valued at $3.50 per share,7,111 shares were bought. As a result of this transaction, RA CAPITAL MANAGEMENT, L.P. now holds 3,403,429 shares worth roughly $17.12 million.
Then, RA CAPITAL MANAGEMENT, L.P. bought 213,099 shares, generating $464,556 in total proceeds. Upon buying the shares at $2.18, the Director now owns 3,294,856 shares.
Before that, RA CAPITAL MANAGEMENT, L.P. bought 101,462 shares. Climb Bio Inc shares valued at $290,181 were divested by the Director at a price of $2.86 per share. As a result of the transaction, RA CAPITAL MANAGEMENT, L.P. now holds 3,396,318 shares, worth roughly $17.08 million.
William Blair initiated its Climb Bio Inc [CLYM] rating to an Outperform in a research note published recently. A number of analysts have revised their coverage, including H.C. Wainwright’s analysts, who began to cover the stock in mid October with a ‘”a Buy”‘ rating. Robert W. Baird began covering CLYM with “an Outperform” recommendation on August 15, 2025. Oppenheimer started covering the stock on June 06, 2025. It rated CLYM as “an Outperform”.
Price Performance Review of CLYM
On Monday, Climb Bio Inc [NASDAQ:CLYM] saw its stock jump 9.83% to $5.03. Over the last five days, the stock has gained 34.13%. Climb Bio Inc shares have risen nearly 140.67% since the year began. Nevertheless, the stocks have risen 25.75% over the past one year.
How much short interest is there in Climb Bio Inc?
A steep rise in short interest was recorded in Climb Bio Inc stocks on 2025-12-15, growing by 0.68 million shares to a total of 2.22 million shares. Yahoo Finance data shows the prior-month short interest on 2025-11-14 was 1.54 million shares. There was a rise of 30.61%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on May 22, 2025 when BTIG Research began covering the stock and recommended ‘”a Buy”‘ rating along with a $7 price target.
